Miura Global Management LLC decreased its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 37.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 170,000 shares of the company's stock after selling 100,000 shares during the period. ARS Pharmaceuticals comprises approximately 2.0% of Miura Global Management LLC's portfolio, making the stock its 22nd biggest holding. Miura Global Management LLC owned 0.17% of ARS Pharmaceuticals worth $1,794,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $73,000. BNP Paribas Financial Markets bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $75,000. Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $106,000. Teacher Retirement System of Texas bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $122,000. Finally, Freestone Grove Partners LP bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $132,000. Institutional investors own 68.16% of the company's stock.
ARS Pharmaceuticals Trading Up 11.6%
Shares of ARS Pharmaceuticals stock traded up $1.41 during trading on Friday, hitting $13.60. The stock had a trading volume of 2,214,443 shares, compared to its average volume of 1,229,178. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -26.67 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51. The business's 50-day moving average is $13.30 and its 200 day moving average is $12.90.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. As a group, equities analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.
Insider Activity at ARS Pharmaceuticals
In related news, insider Eric Karas sold 10,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now owns 7,696 shares of the company's stock, valued at $107,744. This represents a 56.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Laura Shawver sold 50,002 shares of the stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the transaction, the director now directly owns 210,346 shares in the company, valued at approximately $2,587,255.80. This represents a 19.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,602 shares of company stock valued at $1,311,041 over the last 90 days. 33.50% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on SPRY shares. Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price on the stock. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price target on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $31.00.
Get Our Latest Stock Report on SPRY
About ARS Pharmaceuticals
(
Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Further Reading
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
